Skip to content

Marius Nacht

Anchor Investor

Marius Nacht
Marius Nacht

About Marius

Marius is an Anchor Investor at aMoon. In 1993, Marius co-founded Check Point Software Technologies Ltd. (NASDAQ:CHKP), a global pioneer of cybersecurity and the largest company in Israel. He is considered one of the founding fathers of Israel’s global cybersecurity industry.

Marius holds a BSc, cum laude, in Physics and Mathematics, from Hebrew University, and an MSc in Electrical Engineering and Communications Systems from Tel Aviv University. He is a graduate of the IDF elite Talpiyot technological academy.

Press

Steven Mnuchin, Israeli Health Officials Discuss Establishment of Israeli FDA Branch

October 29, 2019

The FDA, which approves all medical devices and formulations in the U.S., has very few branches outside of the U.S.

Read More

aMoon invests in $80m Adicet Bio financing round

October 3, 2019

Based on technology developed by the Technion’s Prof. Yoram Reiter, Adicet Bio is developing allogeneic cell therapies for cancer using innovative gamma delta T cells.

Read More

Marius Nacht Buys Controlling Stake in Universal Flu Vaccine Developer BiondVax

July 17, 2019

Based in Jerusalem, Nasdaq-listed BiondVax develops a universal flu vaccine, currently in advanced clinical trials

Read More

Israel’s Zebra Medical gets FDA ok for AI chest X-ray product

May 13, 2019

Zebra Medical Vision said on Monday it received approval from the U.S. Food and Drug Administration for its artificial intelligence-based chest X-ray triage product.

Read More

Pharma Two B Ltd. Closes $30 Million Financing Round

January 23, 2018

REHOVOTH, Israel, Feb. 27, 2017 /PRNewswire/ — Pharma Two B Ltd., a privately held biopharmaceutical company focused on developing treatments for Parkinson’s disease, announced today it has completed its third round of financing.…

Read More

Marius Nacht to invest $20m in Regenera

January 2, 2018

aMoon Partners, controlled and managed by by Check Point Software Technologies Ltd. (Nasdaq: CHKP) cofounder Marius Nacht, together with Dr. Yair Schindel, is likely to invest $20 million more in pharma company Regenera,…

Read More

Nacht, Harel Insurance invest in personalized cancer treatment

December 7, 2017

Ayala Pharmaceuticals has bought rights from international company Bristol-Myers Squibb (BMS) to develop a personalized treatment for cancer. Ayala, founded a few months ago for this purpose, is an initiative…

Read More

Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments

December 6, 2017

REHOVOT, Israel–(BUSINESS WIRE)–Ayala Pharmaceuticals, a biopharmaceutical company dedicated to developing targeted cancer therapies, announced today that they have entered into an exclusive worldwide license agreement with Bristol-Myers Squibb for two…

Read More

Mapi Pharma Ltd. Announces Closing of $10 Million Investment

August 17, 2017

Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an investment round of $10 million by aMoon Fund. aMoon Fund is an Israeli investment firm focused on innovative Israeli healthcare and life science…

Read More
Scroll To Top